MarketCap
Facebook
X
Telegram
Xenetic Biosciences Market Cap | XBIO
As of October 27, 2026 Xenetic Biosciences has a market cap of $ 2.93 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Xenetic Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.37 M | 3.96 M | 6.04 M | 569 K | 9.77 M | 14.9 M | 4.31 M | 18.6 M | 19.2 M | 35 M | 2.92 M | 2.49 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35 M | 569 K | 10.2 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Curis
CRIS
|
9.48 M | $ 0.38 | -2.33 % | $ 5 M |  USA |
 |
CorMedix
CRMD
|
456 K | $ 7.95 | 1.27 % | $ 573 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 14.37 | 3.53 % | $ 929 M | USA |
 |
NuCana plc
NCNA
|
85.4 B | $ 1.03 | 4.54 % | $ 11.6 B |  Britain |
 |
BioVie
BIVI
|
2.44 M | $ 1.33 | 7.26 % | $ 1.96 M | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.6 | -1.84 % | $ 12.8 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
85.6 M | $ 1.15 | -9.84 % | $ 60.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 60.7 | -0.87 % | $ 7.29 M | USA |
 |
Daré Bioscience
DARE
|
16.9 M | $ 0.64 | -0.33 % | $ 7.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 9.97 | 2.21 % | $ 1.39 B |  France |
 |
Denali Therapeutics
DNLI
|
2.41 B | $ 18.66 | 1.35 % | $ 3.22 B | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.4 | -3.61 % | $ 82.1 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.43 | 7.72 % | $ 15.6 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
43.9 M | $ 0.16 | -7.21 % | $ 7.31 M |  Israel |
 |
Enanta Pharmaceuticals
ENTA
|
259 K | $ 12.0 | 3.09 % | $ 256 K | USA |
 |
Entera Bio Ltd.
ENTX
|
89.6 M | $ 2.83 | -3.25 % | $ 131 M | Israel |
 |
Passage Bio
PASG
|
18.8 M | $ 3.36 | -0.33 % | $ 10.8 M | USA |
|
Forte Biosciences
FBRX
|
335 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 65.14 | 0.95 % | $ 17.7 B | USA |
|
Immatics N.V.
IMTX
|
735 M | $ 7.16 | -2.12 % | $ 876 M |  Germany |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Gilead Sciences
GILD
|
183 B | $ 158.71 | 1.71 % | $ 197 B | USA |
 |
Grifols, S.A.
GRFS
|
4.52 B | $ 7.91 | 4.56 % | $ 5.38 B |  Spain |
 |
GlaxoSmithKline plc
GSK
|
216 B | $ 51.12 | 0.73 % | $ 207 B | Britain |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 128.07 | 1.94 % | $ 15.3 B | USA |
 |
Bio-Techne Corporation
TECH
|
11.3 B | $ 72.69 | 0.2 % | $ 11.3 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 36.84 | 1.97 % | $ 2.12 B | USA |
 |
Immuron Limited
IMRN
|
231 M | $ 0.96 | 0.25 % | $ 222 M |  Australia |
 |
Immunic
IMUX
|
145 M | $ 7.28 | -1.75 % | $ 1.13 B | USA |
 |
Immunovant
IMVT
|
6.49 B | $ 28.19 | -0.79 % | $ 5.14 B | USA |
 |
INmune Bio
INMB
|
28.2 M | $ 1.43 | -2.05 % | $ 35.4 M | USA |
 |
Insmed Incorporated
INSM
|
31.6 B | $ 93.44 | 0.05 % | $ 18.6 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
12.9 B | $ 43.42 | 1.13 % | $ 6.95 B | USA |
 |
Innate Pharma S.A.
IPHA
|
126 M | $ 1.47 | -1.64 % | $ 132 M | France |
 |
Ironwood Pharmaceuticals
IRWD
|
100 M | $ 3.49 | 0.87 % | $ 565 M | USA |
 |
Inventiva S.A.
IVA
|
184 M | $ 3.67 | -1.08 % | $ 219 M | France |
 |
Jazz Pharmaceuticals plc
JAZZ
|
10.5 B | $ 205.67 | -3.89 % | $ 12.5 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
379 B | $ 266.51 | 1.02 % | $ 642 B | USA |
 |
Kamada Ltd.
KMDA
|
490 M | $ 7.93 | 2.06 % | $ 457 M | Israel |
 |
Krystal Biotech
KRYS
|
8.46 B | $ 313.53 | 0.65 % | $ 9.07 B | USA |
 |
Kura Oncology
KURA
|
735 M | $ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
7.93 B | $ 114.86 | 3.7 % | $ 9.7 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
421 M | $ 1.0 | -0.1 % | $ 230 M | USA |
 |
Nanobiotix S.A.
NBTX
|
1.45 T | $ 31.65 | 7.8 % | $ 1.51 T | France |
 |
Longeveron
LGVN
|
16.9 B | $ 1.61 | 0.62 % | $ 28.3 B | USA |
 |
Eli Lilly and Company
LLY
|
940 B | $ 1 277.31 | 0.3 % | $ 1.15 T | USA |
 |
Lipocine
LPCN
|
17.9 M | $ 1.43 | -0.69 % | $ 7.79 M | USA |
|
Larimar Therapeutics
LRMR
|
371 M | $ 2.22 | -5.53 % | $ 184 M | USA |
 |
vTv Therapeutics
VTVT
|
67.6 M | $ 25.97 | 1.64 % | $ 103 M | USA |
 |
Moleculin Biotech
MBRX
|
2.46 M | $ 6.9 | 6.12 % | $ 8.17 M | USA |